Trial Profile

A phase II trial of HRX-215

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 21 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Apr 2025 According to HepaRegeniX media release, the company announced the second closing and completion of a Euro 21.5 million financing round with the addition of Wellington Partners to its investor syndicate. HepaRegeniX plans to use the proceeds to complete its ongoing Phase Ib trial and to advance the Phase IIa clinical trial for HRX215, the companys lead clinical candidate in liver regeneration.
10 Jul 2024 According to HepaRegeniX media release, HepaRegeniX raises 15 million series, Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration
21 Mar 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com